24presse logo   chercher communique Chercher
rappel Etre rappelé
we speak english We speak english!
communiqué de presse

envoyer communiqué de presse

temoignage depuis 2009 tarif
Consultation des communiqués de presse

Précédent
Thème en cours :
Suivant


communiqué affiché 5790 fois sur le site à ce jour
Communiqué de presse Mardi 18 Octobre 2016

Kayentis closes 3.6 M euros growth financing round

Innovation Capital and Extens finance 3.6 M€ round to accelerate the international growth of Kayentis.
 

logo kayentis


Kayentis, a global provider of electronic Clinical Outcome Assessment (eCOA) solutions for patient and data collection in clinical trials, announced today the completion of a 3.6 M€ growth financing round.

The round was led by Innovation Capital whose SISA fund ­‐ dedicated to private equity investments in innovative digital health companies in Europe - contributed the bulk of the financing. The historical investors, Extens, Lénapart and KCE, reinvested alongside Innovation Capital.



Kayentis has specialized in eCOA solutions for patient and data collection in clinical trials since 2009, developing a full range of services and extending its solutions portfolio to  support pharmaceutical companies, biotechnology companies and CROs.

With the experience of more than 120 clinical trials in 75 countries (6,000 sites and 50,000 patients) and in a broad range of therapeutic areas, Kayentis adds value to data quality and clinical trial efficiency with innovative and intuitive solutions, and has two development priorities: Patient Engagement and Risk-­based  Monitoring.

The funds raised will enable Kayentis to further accelerate its growth internationally through increased investments in Sales, Marketing and R&D, and position the company as a leading global provider of eCOA solutions.

"This round of financing validates our development model and our significant growth prospects. It also provides Kayentis with the means to continue improving our technological platform and value-­added services to better serve our clients worldwide. I am particularly pleased to welcome Innovation Capital as a new investor or and business partner to accompany us in this new and exciting growth phase for Kayentis. I also thank the existing investors for their continuous support”, said Guillaume Juge, CEO of Kayentis.

Franck Noiret, General Partner of Innovation Capital, declared: "We are delighted to partner with Kayentis and its experienced management team. This is the 7th investment of our SISA fund dedicated to the financing of innovative digital health companies in Europe. Kayentis has had an impressive track record in the last few years and we are confident it will continue to grow fast. We strongly believe that Kayentis has what it takes to become a leading global provider of eCOA solutions in the next few years."

"Thanks to its portfolio of solutions and quality of service, Kayentis has become a partner of choice in the industry of clinical trials. The strong development of the company confirms our decision to back them two years ago. We have reinvested in this round with the aim to make Kayentis a major eCOA player in the world", added Arnaud Houette, Managing Director of Extens.


About Kayentis

Kayentis is a global provider of electronic Clinical Outcome Assessment (eCOA) solutions for patient data collection in clinical trials. Created in 2003, Kayentis has specialized in eCOA solutions since 2009, developing a full range of services and extending its solutions portfolio to support pharmaceutical companies, biotechnology companies and CROs. Today, with experience of more than 120 clinical trials in 75 countries (6,000 sites and 50,000 patients) and in a broad range of therapeutic areas, Kayentis adds value to data quality and clinical trial efficiency with innovative and intuitive solutions, and has two development priorities: Patient Engagement and Risk-based Monitoring.

Contact : Guillaume JUGE, CEO ­‐ gjuge@kayentis.com ‐ +33 1 69 18 25 40 - Twitter : @MyKayentiswww.kayentis.com


About Innovation Capital

Founded in 1996, Innovation Capital is an international venture capital firm based in Paris with a local presence in the Silicon Valley.

With over €450 million under management, Innovation Capital’s current focus is on venture and growth investments in the digital health space in Europe. The portfolio of the SISA fund currently includes the following companies: Voluntis, Fittingbox, Zesty, Wandercraft, Biomodex, H4D and Kayentis.

Innovation Capital aims to create value by providing talented entrepreneurs with the resources, experience and network necessary to turn innovative technologies and services into great businesses.

Contact : Franck NOIRET, General Partner -­ +33 6 72 81 35 17 ‐ franck.noiret@innovationcapital.fr - www.innovationcapital.fr


About Extens

Founded in 2014, Extens Développement e-­Santé is a sectoral investment vehicle dedicated to the digital transformation of healthcare. Positioned as a growth fund, Extens invests from 1 to 7 M€ in profitable or nearly profitable companies generating 1 to 20 M€ in revenue with strong growth potential. Its investment targets include: software for hospitals, applications software for healthcare professionals, monitoring solutions for patient at home and health data applications. 

Contact : Arnaud HOUETTE, Managing Director - +33 6 70 88 25 98 - arnaud.houette@extens.eu
- www.extens.eu

 

 


Communiqué libre de tous droits de diffusion. Citer source ou lien : 24presse.com

Rédacteur : Kayentis  


Contact presse : Guillaume JUGE
Société : Kayentis
Envoyez un email à Guillaume JUGE
Votre email
Votre message

Saisir le code affiché ci-contre:


5790
 
 
Kayentis
Visiter le site

Satisfait ou remboursé

Si nous rédigeons le communiqué nous vous remboursons si aucun média ne parle de vous dans les 90 jours.
Votre Press Room

Ouvrez une press room pour rassembler toute votre actualité.

Ils nous font confiance

1500 entreprises et associations de toutes tailles nous ont fait confiance depuis 2009.

| | | | |
| | | | |